Abstract 1212P
Background
Severe irAEs caused by ICIs affect treatment efficacy and benefit. Current research on irAEs is mainly focused on early prediction, with a lack of near-term prediction. Studies have reported that baseline neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR) and absolute eosinophil count (AEC) can predict irAEs. Our aim is to explore the near-term predictive value of NLR, PLR, and AEC for grade 3 or higher irAEs caused by PD-1 inhibitors.
Methods
Data were collected from cancer patients treated with PD-1 inhibitors in our department from January 2020 to May 2022. NLR, PLR, and AEC data were collected one cycle before and during the occurrence of irAEs (median cycle number was 2nd and 3rd cycles, respectively). Logistic analysis was used to analyze the correlation between NLR, PLR, AEC, and irAEs, and to construct a prediction model. The model's performance was assessed by obtaining sensitivity and specificity through the ROC.
Results
Out of the 138 cancer patients, 47 experienced grade 1-2 irAEs, and 18 had grade 3 or higher irAEs (including 2 fatal irAEs). Multivariate analysis showed that the current cycle's NLR (OR, 1.839, p=0.000) and PLR (OR, 0.994, p=0.029) were independent risk factors for irAEs. Model A predicted the occurrence of irAEs in the next cycle with an area under the curve (AUC) of 0.788, a sensitivity of 69.2%, and a specificity of 68.5%. When the Model A was ≥38.8% (cutoff value), Model B (AUC =0.900) was entered, predicting the occurrence of grade 3 or higher irAEs in the next cycle with a sensitivity of 67.7% and a specificity of 72.6%. Similarly, Model C predicted the occurrence of irAEs in the current cycle (AUC=0.865) yielded a sensitivity of 81.5% and a specificity of 86.3%. When the Model C was ≥52.8%, Model D was entered, predicting the occurrence of grade 3 or higher irAEs in the current cycle (AUC=0.888) with a sensitivity of 83.3% and a specificity of 83.0%.
Conclusions
The model consisting of NLR, PLR, and AEC in this study can predict the occurrence of grade 3 or higher irAEs within one cycle. Compared with early prediction, our near-term prediction model maximizes the number of cycles of immune therapy obtained by patients, thereby improving the effectiveness of immunotherapy, which has significant clinical value.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1774P - PC-PEP, a comprehensive daily six-month home-based prostate cancer: Patient empowerment program improves quality of life, physical fitness, and urinary function outcomes among prostate cancer patients with localized disease - Secondary analyses of a randomized clinical trial
Presenter: Gabriela Ilie
Session: Poster session 14
1775P - A newly-developed deep-learning algorithm: NAFNet outperforms ResNet50 for predicting adverse pathology events and biochemical recurrence time using MRI from prostate cancer patients
Presenter: Zheng Liu
Session: Poster session 14
1776P - Body composition in adult life and prostate cancer (PCa) incidence and mortality: The PROCA-life study
Presenter: Martin Støyten
Session: Poster session 14
1777P - Enzalutamide (enza) monotherapy for the treatment (tx) of prostate cancer with high-risk biochemical recurrence (BCR): EMBARK secondary endpoints
Presenter: Ugo De Giorgi
Session: Poster session 14
1778P - Treatment (tx) of high-risk biochemically recurrent prostate cancer with enzalutamide (enza) in combination with leuprolide acetate (LA): Secondary endpoints from EMBARK
Presenter: Stephen Freedland
Session: Poster session 14
1779P - PSMA guided approach for bIoCHEmical relapse after prostatectomy-PSICHE trial
Presenter: Giulio Francolini
Session: Poster session 14
1780P - The health inequality impact of darolutamide for non-metastatic castration-resistant prostate cancer: A distributional cost-effectiveness analysis
Presenter: Jeroen Jansen
Session: Poster session 14
1782P - Prostate radiotherapy reduces long-term risk of obstructive uropathy in metastatic hormone sensitive prostate cancer (mHSPC): Results from the STAMPEDE M1|RT comparison
Presenter: Craig Jones
Session: Poster session 14
1783P - PROSTRATEGY: A SOGUG randomized trial of androgen deprivation therapy (ADT) plus docetaxel (dct) +/- nivolumab (nivo) or ipilimumab-nivolumab (ipi-nivo) in high-volume metastatic hormone-sensitive prostate cancer (hvHSPCa) - Efficacy results from the pilot phase
Presenter: Jose Arranz Arija
Session: Poster session 14